Ana Carolina Soares Braga

Ana Carolina Soares Braga

Auto-generated profile, based on publicly available information

Ana Carolina Soares Braga

Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
LGLays Cordeiro Guimaraes
Lays Cordeiro Guimaraes
PCPedro Augusto Carvalho Costa
Pedro Augusto Carvalho Costa
SJSérgio Ricardo Aluotto Scalzo Júnior
Sérgio Ricardo Aluotto Scalzo Júnior
HFHeloísa Athaydes Seabra Ferreira
Heloísa Athaydes Seabra Ferreira
ABAna Carolina Soares Braga
Ana Carolina Soares Braga
PGPedro Guimaraes
Pedro Guimaraes
A safe and effective vaccine with long-term protection against SARS-CoV-2 variants of concern (VOCs) is a global health priority. Here, we develop lipid nanoparticles (LNPs) to provide safe and effective delivery of plasmid DNA (pDNA) and show protection against VOCs in female small animal models. Using a library of LNPs encapsulating unique barcoded DNA (b-DNA), we screen for b-DNA delivery after intramuscular administration. The top-performing LNPs are further tested for their capacity of pDNA uptake in antigen-presenting cells in vitro. The lead LNP is used to encapsulate pDNA encoding the HexaPro version of SARS-CoV-2 spike (LNP-HPS) and immunogenicity and protection is tested in vivo. LNP-HPS elicit a robust protective effect against SARS-CoV-2 Gamma (P.1), correlating with reduced lethality, decreased viral load in the lungs and reduced lung damage. LNP-HPS induce potent humoral and T cell responses against P.1, and generate high levels of neutralizing antibodies against P.1 and Omicron (B.1.1.529). Our findings indicate that the protective efficacy and immunogenicity elicited by LNP-HPS are comparable to those achieved by the approved COVID-19 vaccine from Biontech/Pfizer in animal models. Together, these findings suggest that LNP-HPS hold great promise as a vaccine candidate against VOCs.